about
Polycomb group expression signatures in the malignant progression of gliomas.IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.MicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly targeting p53.Fstl1 Promotes Glioma Growth Through the BMP4/Smad1/5/8 Signaling Pathway.miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.miR-129-5p targets Wnt5a to block PKC/ERK/NF-κB and JNK pathways in glioblastoma.RelB, a good prognosis predictor, links cell-cycle and migration to glioma tumorigenesis.Genome-wide identification of epithelial-mesenchymal transition-associated microRNAs reveals novel targets for glioblastoma therapy.H19 Functions as a Competing Endogenous RNA to Regulate EMT by Sponging miR-130a-3p in GliomaExosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastomaCircular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppressionExosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastomaThe long noncoding RNA ZFAS1 promotes the progression of glioma by regulating the miR-150-5p/PLP2 axismiR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomasFstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastomaExosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastomaLong non-coding RNA SNHG5 promotes glioma progression via miR-205/E2F3 axisA novel circular RNA circFN1 enhances cisplatin resistance in gastric cancer via sponging miR-182-5pS100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF-κB positive feedback loop
P50
Q33599449-5508FB72-8D92-4B65-A968-3D2C8F51A083Q36557547-CBDDE187-050C-4B6E-9789-C61BDA107AC7Q41686929-EE4DD533-8774-4755-92FF-EC5892B2F310Q42378507-C2C5124F-049D-40A3-8557-949230F0AC29Q47323266-DCC73859-F431-4905-A4C1-77DC9B9D2A89Q48597370-8F97FFC8-F70C-48E1-921B-1157B0714C2EQ51417518-F2887398-1CA2-4DD0-AC4C-C58959AEE150Q52655153-E2A754FF-C3CA-48FD-B552-C332BE6DFACCQ54945100-174FE2B8-D65A-4A9C-8E5A-BE6ADD9911EFQ57035177-21C887B2-E6F8-4E38-8308-5CE950B2AF63Q64057602-88741218-0444-4E84-BAFC-02FF28301BD4Q64100312-0DAA10A5-3274-4261-85FC-0CAC9EC6C6A0Q64109379-2817FA01-B0B1-4AB3-B2F7-CE6DF791F188Q90174184-9C42E479-B165-40FE-B8C0-960B36BE87ABQ90326866-CDDDC31B-F137-4705-B846-DFBC84F07EC6Q90440161-D084BE80-AF8E-4711-B7C3-EEA353DD0E02Q90918715-4E36108A-FD11-40C5-A8EE-2B0CAAABEB59Q91775044-0BC0AF36-7896-46AA-8355-510C6D93424DQ92391217-6233536D-E3CB-4972-97F7-DB5A55984981Q92725333-5E5263D4-DC71-4D9C-81A4-68B46E329B49
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Ailiang Zeng
@en
Ailiang Zeng
@nl
type
label
Ailiang Zeng
@en
Ailiang Zeng
@nl
prefLabel
Ailiang Zeng
@en
Ailiang Zeng
@nl
P31
P496
0000-0003-2869-9899